Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + fludarabine phosphate
- Development stage
- Phase 3
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This entry refers to a specific non-myeloablative conditioning regimen evaluated in a Phase II clinical trial conducted by the Roswell Park Cancer Institute. The protocol utilizes a combination of the alkylating agent **cyclophosphamide** and the purine antimetabolite **fludarabine phosphate** to prepare patients for allogeneic hematopoietic stem cell transplantation. This regimen is designed to provide sufficient immunosuppression to allow for donor cell engraftment and the subsequent induction of a graft-versus-tumor effect, while minimizing the severe systemic toxicities typically associated with traditional myeloablative conditioning. It is primarily investigated for use in patients with various hematologic malignancies (such as leukemia and lymphoma) or aplastic anemia who are ineligible for intensive transplant protocols due to age or comorbidities.
- Other names
- Flu/Cy conditioningNon-myeloablative conditioning with cyclophosphamide and fludarabine
02
Targets
DNALIG1 (DNA ligase 1)POLA1 (DNA polymerase alpha)DNA-directed primase/polymerase protein (PrimPol)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on cyclophosphamide + fludarabine phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + fludarabine phosphate.